New EU Harmonised Standards for Medical Devices in 2026

The new EU harmonised standards for medical devices published in 2026 affect biological safety, sterilisation, clinical investigations, electrical equipment, labelling, implants, washer-disinfectors and several product-specific categories. Manufacturers need to map the changes to their technical documentation, while buyers should verify whether suppliers have assessed the latest references before approving products.

Under Article 8 of the EU Medical Device Regulation, compliance with a relevant harmonised standard whose reference appears in the Official Journal of the European Union creates a presumption of conformity with the MDR requirements covered by that standard. Use remains voluntary, but manufacturers choosing another method must still demonstrate that their device meets the applicable general safety and performance requirements (European Commission, 2026).

Three MDR harmonised standards updates in 2026

The European Commission updated the MDR harmonised standards list three times during the first half of 2026.

The January package added 12 references covering hydrocephalus shunts, blood-contact evaluation, clinical investigations, non-active implants, moist-heat sterilisation, breathing-gas pathways, hip and knee implants, and respiratory connectors. These included EN ISO 14155:2020/A11:2024 for clinical investigations and EN ISO 17665:2024 for moist-heat sterilisation (European Commission, January 2026).

The April package added EN 13060:2025 for small steam sterilisers, EN 14222:2021+A1:2025 for stainless-steel steam boilers and EN IEC 60118-0:2024 for hearing-aid performance measurement (European Commission, April 2026).

The largest update arrived through Commission Implementing Decision (EU) 2026/1231, published on 17 June. It added 14 new references and amended five existing entries under the MDR (European Commission, June 2026).

Medical device standards affected by the June update

Biological evaluation received the most significant attention. The new references include EN ISO 10993-1:2025, which addresses biological safety evaluation within a risk-management process, and an amendment to EN ISO 10993-5 for in vitro cytotoxicity. Amendments also affect irritation testing, sample preparation and toxicological risk assessment.

Manufacturers of medical electrical equipment should review the amendment to EN 60601-1 and the updated particular standard for home light-therapy equipment. Other product areas covered include single-use transfusion sets, spectacle frames and lenses, mammary implants, ankle-foot prosthetic devices and sharps-protection mechanisms.

Healthcare facilities and equipment suppliers should also note the revised EN ISO 15883 series for washer-disinfectors. The references cover general requirements, thermal disinfection for critical and semi-critical devices, human-waste containers and chemical disinfection for non-critical thermolabile equipment (European Commission, June 2026).

Longer transition for the authorised representative symbol

EN ISO 15223-1:2021/A1:2025 updates the symbols standard used in manufacturer-supplied information. The amendment adds a defined term for an authorised representative and modifies the EC REP symbol so it is no longer country- or region-specific.

The revised reference became available when the decision entered into force. However, deletion of the previous EN ISO 15223-1 entry will apply from 15 June 2031. Several other replaced entries, including standards for irritation testing, sample preparation, home light therapy and toxicological risk assessment, are scheduled for deletion from 15 December 2027 (European Commission, June 2026).

These dates create transition windows rather than permission to postpone all action. Manufacturers should assess the revised content now, determine whether design, testing, risk files or labelling changes are required, and document the implementation plan.

New IVDR harmonised standards in 2026

A separate January decision updated the harmonised standards supporting the In Vitro Diagnostic Medical Devices Regulation. It added EN ISO 17665:2024 for moist-heat sterilisation and the five-part EN ISO 18113:2024 series covering information supplied by manufacturers of professional-use and self-testing IVD reagents and instruments (European Commission, January 2026).

IVD companies should maintain a separate IVDR standards register. Applying an MDR reference to an IVD without checking the relevant IVDR decision can produce an incomplete conformity strategy.

What medical device manufacturers should do now

First, update the standards register for each device family. Record the applicable regulation, current OJEU reference, publication date, superseded version, transition date and technical-documentation location.

Second, complete a documented gap assessment. Compare each revised clause with existing risk management, biological evaluation, verification and validation, clinical, sterilisation, electrical-safety and labelling evidence.

Third, decide whether new testing is necessary. A revised standard does not automatically require repeating every test, but the justification for using existing evidence must be technically sound and traceable.

Finally, coordinate changes with the notified body where the update affects certified devices, planned submissions or significant elements of the conformity assessment.

What medical device buyers should verify

Procurement teams should not accept “CE certified” as the end of the review. Ask the supplier for a device-specific list of applied standards, the version used for testing and confirmation that the 2026 changes were assessed.

For affected products, request supporting reports or summaries covering biological safety, sterilisation validation, electrical safety, clinical investigation controls or labelling. Where an older reference remains within a transition window, ask for the manufacturer’s documented migration plan and target completion date.

Distributors should place these requirements in supplier questionnaires and quality agreements. This creates a clear obligation to communicate standards changes that could affect product compliance, labels, test evidence or market availability.

Practical compliance takeaway

The 2026 publications do not make every new standard universally mandatory. They do, however, change the most defensible route to demonstrating conformity for many medical devices and IVDs. Manufacturers should complete device-level gap assessments, and buyers should incorporate standards-version checks into supplier qualification.

When sourcing through Suplivia, verification tiers can support the initial manufacturer screen, but buyers should still request the current standards matrix and product-specific conformity evidence before placing an order.